|
Report Date : |
11.06.2012 |
IDENTIFICATION DETAILS
|
Name : |
KOA SHOJI CO LTD |
|
|
|
|
Registered Office : |
7-13 Hiyoshi Kohokuku |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
30.06.2011 |
|
|
|
|
Date of Incorporation : |
February 1991 |
|
|
|
|
Com. Reg. No.: |
(Yokohama-Kohokuku) 020100 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Import, export, wholesale of pharmaceutical ingredients, generic medicines |
|
|
|
|
No. of Employees : |
50 |
RATING & COMMENTS
|
MIRAs Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
Regular |
|
Litigation : |
-- |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
KOA SHOJI CO LTD
REGD NAME: Koa
Shoji KK
MAIN OFFICE: 7-13
Hiyoshi Kohokuku
Tel:
045-560-6081 Fax: 045-560-6082
*.. Registered at:
2-17-5 Minowacho Kohokuku
E-Mail address: info@koashoji.com
Import, export,
wholesale of pharmaceutical ingredients, generic medicines
Pharmaceutical mfg
license: category (packaging, labeling & storing)
TOSHIYUKI SHUTO,
PRES
Koichi Okazawa,
s/mgn dir
Toshiaki Ishiwata,
mgn dir
Yen Amount: In million Yen, unless otherwise stated
FINANCES FAIR A/SALES Yen 7,618 M
PAYMENTS REGULAR CAPITAL Yen 20 M
TREND STEADY WORTH Yen 2,547 M
STARTED 1991 EMPLOYES 50
TRADING HOUSE SPECIALIZING IN PHARMACEUTICAL RAW MATERIALS &
INGREDIENTS.
FINANCIAL SITUATION CONSIDERED FAIR AND GOOD
FOR ORDINARY BUSINESS ENGAGEMENTS.
The subject company was established by
Masakazu Nagase in order to make most of his experience in the subject line of
business. Toshiyuki Shuto, a graduate of
Meiji College of Pharmacy, assumed the pres office in Sept 1997. This is a trading house specializing in
import, export and wholesale of active pharmaceutical raw materials &
ingredients, generic pharmaceuticals, other.
Goods are imported as licensed importer.
Goods are also packaged, labeled and stored (including cold &
freezing) at its own yard. Acts as proxy
of Japanese pharmaceuticals for export.
Financials are only partially
disclosed.
The sales volume for Jun/2011 fiscal term amounted to Yen 7,618 million,
a 14% up from Yen 6,700 million in the previous term. Pharmaceutical Affairs Law was revised in Apr
2005 and import of pharmaceutical materials & ingredients were
deregulated. Sales of generic
pharmaceuticals expanded. The net profit
was posted at Yen 821 million, compared with Yen 580 million a year ago.
For the current term ending Jun 2012 the net
profit is projected at Yen 840 million, on a 3% rise in turnover, to Yen 7,850
million. Business is steadily
expanding.
The financial situation is considered FAIR
and good for ORDINARY business engagements
Date Registered:
Feb 1991
Regd No.:
(Yokohama-Kohokuku) 020100
Legal Status: Limited Company (Kabushiki Kaisha)
Authorized: 1,600 shares
Issued:
400 shares
Sum: Yen 20 million
Major
shareholders (%): Toshiyuki Shuto (50.3), Masakazu Nagase (46.9), Employees S/Holding
Assn (2.8)
No. of shareholders: 3
Nothing
detrimental is known as to the commercial morality of executives.
Activities: Trading house for
import, export and wholesale of active pharmaceutical raw materials &
ingredients, generic medicines, others (--100%).
Goods are, under license, packaged, labeled
and stored (including cold & freezing) at its own yard.
(Typical
Items of import):
Pravastatin, Simvastatin, Etodolac, Omeprazole,
Itracenazole, Doxazosin, Mosylate, Milrinone, Fluticasone Propionate,
Resperidone, Benidipine HCI, Fenofibratel, Ondansetron HCI, Actarit, Pranlukast
Hydrate, other (from the firms list of products).
Clients: [Pharmaceutical
mfrs, chemical mfrs, wholesalers] Nippon Kayaku Co, Taisho Pharmaceutical,
Azwell Inc, Sawai Pharmaceutical, Wako Pure Chemical Ind, Medisa Shinyaku,
Kobayashi Kako, Alfresa Pharma, Sannova Co, Ace Trading, Towa Pharmaceutical,
Tatsumi Kagaku, Kyorin Rimedio Co, other.
No. of accounts:
500
Domestic areas of
activities: Nationwide
Suppliers: [Mfrs,
wholesalers] Teva, Summit Chemical, Honeywell PFC, Biochemie, Profarma Co,
Plantex, Ivax, other.
Domestically supplied from: Yoshindo Inc,
Eisai Food Chemical, other.
Payment record: Regular
Location: Business area in
Bank References:
MUFG
(Musashi-Kosugi)
Mizuho Bank
(Musashi Kosugi)
Relations:
Satisfactory
(In
Million Yen)
|
|
|
30/06/2012 |
30/06/2011 |
30/06/2010 |
30/06/2009 |
|
Annual
Sales |
|
7,850 |
7,618 |
6,700 |
6,532 |
|
Recur.
Profit |
|
|
|
|
|
|
Net
Profit |
|
840 |
821 |
580 |
614 |
|
Total
Assets |
|
|
N/A |
N/A |
N/A |
|
Net
Worth |
|
|
2,547 |
1,950 |
1,544 |
|
Capital,
Paid-Up |
|
|
20 |
20 |
20 |
|
Div.P.Share(₯) |
|
|
20.00 |
20.00 |
0.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
3.05 |
13.70 |
2.57 |
10.90 |
|
|
Current Ratio |
|
|
.. |
.. |
.. |
|
N.Worth Ratio |
|
.. |
.. |
.. |
|
|
N.Profit/Sales |
10.70 |
10.78 |
8.66 |
9.40 |
|
Notes: Financials
are only partially disclosed.
Forecast (or
estimated) figures for the 30/06/2012 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.36 |
|
|
1 |
Rs.85.64 |
|
Euro |
1 |
Rs.69.21 |
INFORMATION DETAILS
|
Report Prepared
by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SCs credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.